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Abstract
Anthracycline daunorubicin (DNR) is one of the major antitumor agents widely used in the treatment of myeloid leukemia.
Unfortunately, the clinical efficacy of DNR was limited because of its cytotoxity at high dosage. As a novel cytoprotective
mechanism for tumor cell to survive under unfavorable conditions, autophagy has been proposed to play a role in drug
resistance of tumor cells. Whether DNR can activate to impair the sensitivity of cancer cells remains unknown. Here, we first
report that DNR can induce a high level of autophagy, which was associated with the activation of extracellular signal-
regulated kinase 1/2 (ERK1/2). Moreover, cell death induced by DNR was greatly enhanced after autophagy inhibition by the
pharmacological inhibitor chloroquine (CQ) and siRNAs targeting Atg5 and Atg7, the most important components for the
formation of autophagosome. In conclusion, we found that DNR can induce cytoprotective autophagy by activation of ERK
in myeloid leukemia cells. Autophagy inhibition thus represents a promising approach to improve the efficacy of DNR in the
treatment of patients with myeloid leukemia.
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Introduction
Myeloid leukemia is a heterogeneous group of diseases
characterized by uncontrolled proliferation of neoplastic hemato-
poietic precursor cells and impaired production of normal
hematopoiesis leading to neutropenia, anemia, and thrombocyto-
penia [1]. Anthracycline daunorubicin (DNR) is one of the major
antitumor agents widely used in the treatment of myeloid
leukemia. The toxicities of DNR include cardiac toxicity, renal
toxicity, severe myelosuppression, et al [2,3,4]. Cytotoxicities
induced by DNR are mainly caused by drug-induced damage to
DNA and production of free radicals which are initiated by
reactive oxygen species (ROS) [5,6]. Since the dosage used is
critical to the incidence of DNR–induced toxicities, it would be
important to reduce the dosage of DNR by increasing the
sensitivity of leukemia cells to DNR.
Macroautophagy (hereafter referred to as autophagy) is a
degradative process in eukaryotic cells that results in the
breakdown of intracellular material within lysosomes [7,8]. Under
cellular stress conditions such as nutrient-deprivation, DNA
damage and elevation of intracellular ROS, autophagy could be
activated to provide an alternative source of energy to enable cell
survival [9,10,11]. Excessive or unquenched autophagy, however,
can lead to type II programmed cell death (PCD II), which is
morphologically distinct from apoptosis and usually caspase
independent [12]. In tumor cells, the role of autophagy may
depend on the type of tumors, the stage of tumorigeneses, the
nature and extent of the insults. Autophagy was upregulated
during the later stages of cancer development so that cancer cells
could survive in the central areas of the tumour which are usually
poorly vascularized and lack of nutrient and oxygen [13,14,15]. A
number of anticancer therapies, including DNA-damaging
chemotherapeutic drugs, have been observed to induce the
accumulation of autophagosomes in tumor cell lines and inhibition
of autophagy by pharmacologic inhibitor or genetic knockdown of
phylogenetically conserved autophagy-related genes, such as Atg5
and Atg7, usually enhanced drug-induced cytotoxicities [12]. In
our previous research, we found that gefitinib induced autophagy
in lung cancer cells and inhibiting autophagy increased the
sensitivity of lung cancer cells to gefitinib, suggesting a novel
approach to enhance target therapy of lung cancer [16].
In the present study, we demonstrated that DNR induced
autophagy in myeloid leukemia cells by ERK1/2 activation. And
DNR-induced apoptosis was enhanced after the inhibition of
autophagy, suggesting a novel and promising strategy to increase
the clinical efficacy of DNR for the treatment of myeloid
leukemia.
Materials and Methods
Reagents and antibodies
Daunorubicin (DNR) and chloroquine (CQ) were purchased
from J&K chemical Ltd., China. Monodansylcadaverine (MDC),
U0126 and Hoechst were purchased from Sigma-Aldrich. Primary
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(LC3), Atg5, Atg7, Beclin-1, caspase 3, caspase 9, PARP,
GAPDH, non-phospho- or phospho-MEK1/2 and ERK1/2 were
from Cell Signaling Technology, Inc.. The secondary antibodies
were HRP conjugated anti-rabbit and anti-mouse IgG (Cell
Signaling Technology, Inc.).
Cell cultures and transfection
K562 were bought from cell bank (Chinese Academy of
Sciences). Cells was maintained in RPMI 1640 supplemented
with 10% (v/v) FBS. Stock solution of U0126 was prepared in
dimethyl-sulphoxide (DMSO, Sigma) and diluted with medium
before use. Final concentration of DMSO was ,0.1%. The tfLC3
tandemly tagged with GFP and mRFP construct were obtained
from Addgene. Transfection was performed via electroporation
with a Nucleofection system (Amaxa, Inc.) according to the
manufacturer’s instructions. Stable transformants were selected in
complete medium containing 500 mg/ml G418 (Sigma).
Cytotoxicity assay
The cytotoxicity of chemicals against K562 cells was deter-
mined by MTT assay. Cells were seeded into 96-well plates and
treated with chemicals with different concentrations. After 48-h
incubation, 20 ml MTT (5 mg/ml) was added into each well for 4-
h incubation and 150 ml DMSO was added into each well in order
to solubilize the blue-purple crystals of formazan afterwards. The
absorbance was then measured using a model ELX800 Micro
Plate Reader (Bio-Tek Instruments, Inc.) at 570 nm.
MDC-staining and Hoechst-staining
MDC was stored at220uC under desiccant. A fresh stock
solution of 5 mM MDC was made in 1:1 DMSO immediately
prior to use. At 1 hour before fixation, fresh medium that
contained either 10 mM MDC in DMSO or an equivalent volume
of DMSO was added to the cells. The cells were fixed using a
freshly made 4% formaldehyde solution in PBS for 10 min. at
room temperature and imaged immediately.
For identification of cells with nuclear changes typical of
apoptosis, cells were stained with 5 mg/ml of Hoechst 33342 for
10 min. at 4uC in the dark and analyzed using a UV microscope.
Immunofluorescence and confocal microscopy
Cells were collected, fixed and permeabilized with 1% CHAPS
buffer (150 mM NaCl, 10 mM HEPES, 1.0% CHAPS) at room
temperature for 10 min, incubated with anti-LC3 for 2 h at room
temperature, and washed with PBS, incubated for another 45 min
with FITC-conjugated goat anti-rabbit IgG (Beyotime, A0562).
Then, cell nuclei were stained by DAPI (Sigma, D9564). Samples
were examined under a Zeiss LSM 710 confocal microscope
system (Carl Zeiss, Germany). Image was processed with ZEN LE
software.
For evaluating tandem fluorescent LC3 puncta, stable transfor-
mants after treatment were washed with PBS, fixed with 4%
paraformaldehyde, mounted with DAPI and viewed under the
confocal microscope.
Electron microscopy
Treated cells were washed and fixed for 30 min in 2.5%
glutaraldehyde. The samples were treated with 1.5% osmium
tetroxide, dehydrated with acetone and embedded in Durcupan
resin. Thin sections were poststained with lead citrate and
examined in the TECNAI 10 electron microscope (Philips,
Holland) at 60 kV.
Western blot analysis
Western blotting was carried out as previously reported [17].
Briefly, proteins were resolved by SDS-polyacrylamide gel
electrophoresis, transferred to a PVDF membrane and then
detected by the proper primary and secondary antibodies before
visualization with a chemiluminescence kit (Pierce). The visuali-
zation was done with Image Quant LAS-4000 (Fujifilm, Tokyo,
Japan).
RNA interference
K562 cells were transfected with either nonspecific or Atg5/
Atg7 RNA interference (All siRNAs were from Qiagen, RNAi;
final concentration, 100 nmol/L) via LipofectAMINE 2000
(invitrogen) according to the manufacturer’s instructions. Cells
were then incubated for 48 h prior to Western blot or MTT assay.
For Beclin-1 RNA interference, two siRNA oligonucleotides
targeting Beclin-1 were bought from Cell Signaling Tech (#6222
& 6246). A nonspecific oligo that is not complementary to any
human genes was used as a negative control. To transfect K562
cells, HiPerFect reagent (QIAGEN) was used following the
manufacturer’s protocol.
Statistical analyses
Unless otherwise stated, data were expressed as the mean 6 SD
and analyzed by Student’s t test.
Results
DNR induced apoptosis in K562 cells
K562 cells were incubated in the presence of varying
concentration of DNR for 24 hours and subjected to morpholog-
ical and biochemical examinations. A dose-dependent nuclear
morphology changes were observed (Fig. 1A). Cells had typical
morphology of apoptosis such as nuclear chromatin condensation
and nuclear fragmentation. Biochemically, caspase 3 and 9 were
activated by DNR in a dose-dependent manner (Fig. 1B).
Consistently, the level of cleaved product of caspases substrate
Poly ADP-ribose Polymerase (PARP) was correlated with the
activation of caspases (Fig. 1B). Collectively, these results
demonstrated that DNR could induce apoptosis in K562 cells.
DNR activated autophagy in K562 cells
To evaluate the activation of autophagy by DNR, the
conversion of LC3-I into LC3-II before and after DNR treatment
was first determined by western blotting analysis. DNR can induce
the switch of LC3-I to LC3-II in the dose and time dependent
manner in K562 cells, indicating that autophagy might be
activated by DNR (Fig. 2A). Consistently, Beclin-1, a regulator
of autophagic pathway, was significantly up-regulated in DNR-
treated cells (Fig. 2B). Moreover, DNR treated cells were stained
with monodansylcadaverine (MDC), a fluorescent dye selectively
recognizing autophagosomes and autolysosomes [18]. As shown in
Figure 2C, DNR treated cells revealed a diffuse punctuate pattern
which indicates the activation of autophagy while the control cells
show faint fluorescent. After the treatment of Chloroquine (CQ)
which can disrupt the function of lysosomes and inhibit autophagy
at late stage, DNR treatment resulted in the accumulation of large
MDC-positive vesicles, confirming the activation of autophagy by
DNR (Fig. 2C). To further confirm it, the distribution of
endogenous LC3-II in cells before and after DNR treatment was
monitored by indirect immunofluorescence staining. Indeed,
specific punctate distribution of endogenous LC3-II was seen in
the K562 cells treated with DNR (Fig, 2D).
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further confirmed that large autophagic vacuoles with typical
double-layer membrane containing organelle remnants presented
in DNR-treated K562 cells rather than untreated cells (Fig. 3).
Besides, K562 cells treated with 2.5 mg/ml DNR for 12 hours
displayed a typical nuclear morphology of apoptosis such as
chromatin condensation and nuclear fragmentation (Fig. 3D).
Blockage of autophagy enhanced DNR-induced K562 cell
death
Many studies have demonstrated that autophagy may serve as a
protective response preventing tumor cells from therapy-induced
cell death [10]. To test this consumption, we compared the growth
inhibitory effect of DNR on cancer cells before and after
pharmacological and genetic inhibition of autophagy. As shown
in Figure 4A, CQ failed to inhibit K562 cell growth by its own.
However, it significantly inhibited the autophagy induced by DNR
(Figure S1) and augmented growth inhibition induced by DNR as
well as DNR-induced caspase activation (Fig. 4B)[19].
Autophagy is tightly regulated by several highly conserved
molecules called ATGs [11]. Since ATGs are essential to the
activation of autophagy, siRNAs specific to human Atg5 and Atg7
were used to block autophagy after DNR treatment (Fig. 5A and
B). Consistent with the pharmacological inhibition of autopahgy,
growth inhibition induced by DNR was markedly enhanced after
autophagy was blocked by the knockdown of Atg5 and Atg7
(Fig. 5A and B), confirming that DNR-activated autophagy is
cytoprotective.
As mentioned above, Beclin-1, a regulator of autophagic
pathway, was significantly up-regulated in DNR-treated cells
(Fig. 2B). This result prompted us to investigate if knockdown of
Beclin-1 will impair DNR induced autophagy? As expected,
knockdown of beclin-1 could significantly decrease the number of
puncta LC3 induced by DNR (Fig. 5C&D). And we also measured
the cytotoxiciy of DNR against K562 cells transfected with beclin-
1 siRNAs. Inhibition of autophagy by knockdown of beclin-1
sensitized K562 cells to DNR (Fig5. E).
DNR induced autophagy by activating of MEK/ERK
signaling pathway
It have been reported that autophagy was associated with
MAPK signaling pathway [20,21,22,23]. Therefore, we deter-
mined the relevance of this pathway to DNR-induced autophagy.
Indeed, phosphorylation of MEK1/2 and ERK1/2 were signif-
icantly increased after DNR treatment (Fig. 6A). Pre-treatment of
K562 cells with the MEK1/2 inhibitor U0126 resulted in the
decrease of LC3-II levels (Fig. 6A), indicating the dependence of
autophagy on the activation of MAPK signaling. In consistence
with previously finding (Fig 4 and 5), U0126 significantly
augmented DNR-induced growth inhibition of K562 cells
(Fig. 6B).
Discussion
Anthracycline daunorubicin is one of the major antitumor
agents widely used in the treatment of myeloid leukemias.
Cytotoxicity mediated by DNR is generally thought to be the
result of drug-induced damage to DNA. Interestingly, previous
studies demonstrated that DNR triggered both apoptotic and
survival pathways. The phospholipase C–dependent DAG/raf-1/
MEK cascade and DAG independent PI3K/PKCf cascade play a
significant role in DNR induced cellular survival pathways [24].
As well known, both raf-1/MEK and PI3K cascade are involved
in the autophagy signaling [11,25]. In addition to DNR, many
other DNA-damaging drugs have been confirmed to activate
autophagy in various tumor cell lines and inhibition of autophagy
by pharmacologic inhibitors or genetic knockdown of critical
autophagy-related genes such as Atg5 and Atg7 could enhance the
anti-cancer effect of chemotherapeutic drugs [10]. However, very
little was known about the relevance of autophagy in the response
of myeloid leukemia cells to DNR treatment. This study, for the
first time, demonstrated that DNR can induce cytoprotective
autophagy in K562 cells by the activation of MEK/ERK signaling
pathway.
Autophagy is morphologically characterized by the appearance
of ‘‘double-membrane’’ vacuoles, autophagosomes, in the cyto-
Figure 1. DNR induced apoptosis in K562 cells. A. K562 cells were treated with DNR for 24 hours, and stained by Hoechst. B. Cells were treated
with varying concentration of DNR for 24 hours and examined for activation of caspases 3, 9 and cleavage of PARP with Western Blotting analysis.
doi:10.1371/journal.pone.0028491.g001
Activation of Cytoprotective Autophagy by DNR
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28491plasm. In addition, LC3, the mammalian homologue of the yeast
protein Apg8p, was found to be a specific biochemical marker for
autophagy. Newly synthesized LC3 termed LC3-I is evenly
distributed throughout the cytoplasm. Upon the induction of
autophagy, some LC3-I is converted into LC3-II which is tightly
bound to the autophagosomal membranes, forming ring-shaped
structures in the cytosol. We confirmed biochemically and
morphologically that autophagy was activated by DNR in K562
cell lines (Fig. 2 and 3).
In addition, we found that DNR could induce both apoptosis
and autophagy in K562 cells (Fig.3 D and E). Inhibition of
autophagy enhanced the activation of caspases as well as the
tumor inhibition induced by DNR (Fig. 4 and Fig. 5). Based on the
EM results, we postulated that autophagy activated by DNR in
K562 cells was probably earlier than apoptosis. When K562 cells
treated with DNR for 6 hours, we could find numerous
autophagical vacuoles with typical double-layer membrane
containing organelle remnants in most of cells while the apoptotic
changes of nuclei were less observed. However, chromatin
condensation and nuclear fragmentation were easier to find only
after K562 cells were treated with DNR for 12 hours. This result
was consistent with previous reports that autophagy preceded
apoptosis in many cancer cells treated with various cytotoxic drugs
[26,27,28].
As one critical signaling pathways involved in tumorigenesis,
MAPK signaling pathway are often activated in numerous types of
cancer cells. Accumulating evidences indicated that the activation
of ERK1/2 was associated with autophagy [22,23,29,30,31]. In
our study, we found that DNR indeed activated MEK1/2 and
ERK1/2. Inhibition of MEK1/2 by U0126 inhibited the shift
from LC3-I to LC3-II, thus enhancing the cytotoxic effect of
DNR. Previous studies indicted that the constant activation of
MEK/ERK signaling in tumor cells could up-regulate Beclin-1,
eventually activating autophagy [23]. Indeed, Belin 1 expression in
K562 cells was increased after DNR treatment (Fig. 2B).
Knockdown of beclin-1 could significantly decrease the number
of puncta LC3 induced by DNR (Fig. 5C&D), and sensitized K562
cells to DNR treatment (Fig. 5E).
Figure 2. DNR induced autophagy in K562 cells. A. K562 cells were incubated with varying concentrations of DNR for 24 hours or incubated
with 1.25 mg/ml DNR for appropriate intervals. The switch of LC3-I to LC3-II was detected by immunoblotting. B. Immunoblotting for Beclin-1 using
lysates from K562 treated with 1.25 mg/ml DNR for appropriate intervals. C. MDC staining of K562 treated with DNR. Cells treated with 1.25 mg/ml
DNR in the presence or absence of 5 mM CQ for 24 hours were stained with MDC. D. K562 cells were treated with 1.25 mg/ml DNR for 24 hours, and
stained by indrect immunofluorescence as described in Marterial & Methods. The distribution of endogenous LC3 was monitored at confocal
microscope.
doi:10.1371/journal.pone.0028491.g002
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growth inhibition as well as cytoprotective autophagy in myeloid
leukemia cells. Blocking autophagy by autophagy inhibitors or
inhibitors of MAPK signaling is a promising therapeutic strategy
to enhance tumor inhibition induced by DNR and probably other
chemotherapeutic drugs.
Figure 3. TEM depicted ultrastructures of K562 cells treated with DNR. Cells treated without (A) or with 2.5 mg/ml DNR for 6 hours (B, low
power; C, high power) and 12 hours (D, low power; E, high power) were subjected to TEM analysis. Autophagosomes were highlighted by white
arrows in C and E while apoptotic changes such as chromatin condensation and nuclear fragmentation were highlighted by black arrows in D. Bar
=1mm.
doi:10.1371/journal.pone.0028491.g003
Figure 4. Autophagy inhibitor CQ enhanced DNR-induced apoptosis in K562 cells. A. Cells were treated with varying concentration of DNR
for 48 hours in the presence or absence of 5 mM CQ. Cell viability was then measured by MTT assay. B. Immunoblotting of caspase 3, caspase 9 and
PARP using lysates from K562 cells as treated in A. Data were expressed as the mean 6 SD, and analyzed by Student’s t test. *, P,0.05 and **, P,0.01.
doi:10.1371/journal.pone.0028491.g004
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PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28491Figure 5. Depletion of autophagy genes enhanced DNR-induced apoptosis in K562 cells. A & B, Cells transiently transfected with negative
control siRNA, Atg7 or Atg5 siRNA were treated with varying concentration of DNR for 48 hours. Cells viability was measured by MTT assay and the
expression of Atg5 and Atg7 were determined by Immunoblotting. NC, negative control; C, Cells were transiently transfected with negative control
siRNA or beclin-1 targeting siRNAs, and the expression of beclin-1 was determined by western blot. D, Cells were treated with 1.25 mg/ml DNR for 24
hours, and stained by indrect immunofluorescence as described in Marterial & Methods. The distribution of endogenous LC3 was monitored at
confocal microscope. Green, FITC labelled LC3; blue, DAPI stained nuclei. E, Cells transiently transfected with beclin-1 targeting siRNAs were treated
with 1.25 mg/ml DNR for 48 hours, and the viability was measured by MTT assay. Data were expressed as the mean 6 SD, and analyzed by Student’s
t test. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0028491.g005
Figure 6. Activation of autophagy by DNR was MEK/ERK-dependent. A, K562 cells were treated with 1.25 mg/ml DNR for 24 hours in the
presence or absence of 5 mM U0126 and the switch of LC3-I to LC3-II as well as the phosphorylation of MEK 1/2 and ERK1/2 were determined by
Immunoblotting. B, Cells were treated with varying concentration of DNR for 48 hours in the presence or absence of 5 mM U0126. Cells viability was
measured by MTT assay. Data were expressed as the mean 6 SD, and analyzed by Student’s t test. * P,0.05.
doi:10.1371/journal.pone.0028491.g006
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Figure S1 CQ inhibited DNR-induced autolysosomes
formation. K562 cells with stable expression of tfLC3 were
treated with 1.25 mg/ml DNR for 24 hours in the presence or
absence of 5 mM CQ. mRFP and GFP were monitored at confocal
microscope as described in M&M. The red puncta that overlay
with the green puncta and appear yellow in merged images are
indicators of autophagosomes, whereas the free red puncta that do
not overlay with the green puncta and appear red in merged
images are indicative of autolysosomes [19].
(TIF)
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